key: cord-0983932-fumc4r0f authors: Xia, Pu; Dubrovska, Anna title: Tumor markers as an entry for SARS‐CoV‐2 infection? date: 2020-08-01 journal: FEBS J DOI: 10.1111/febs.15499 sha: 0edfe66536136361cdc7ae9bbf96b9afa91737fe doc_id: 983932 cord_uid: fumc4r0f Coronavirus disease 2019 (COVID‐19), the highly contagious illness caused by a novel severe acute respiratory syndrome coronavirus 2 (SARS‐CoV‐2), has spread across the globe, becoming one of the most challenging public health crisis of our times. SARS‐CoV‐2 can cause severe disease associated with multiple organ damage. Cancer patients have a higher risk of SARS‐CoV‐2 infection and death. While the virus uses angiotensin‐converting enzyme 2 (ACE2) as the primary entry receptor, the recent experimental and clinical findings suggest that some tumor markers, including CD147 (Basigin), can provide a new entry for SARS‐CoV‐2 infection through binding to the viral spike (S) protein. In the absence of specific viral drugs, blocking of CD147 might be a way to prevent virus invasion. Identifying other target proteins is of high importance as targeting the alternative receptors for SARS‐CoV‐2 might open up a promising avenue for the treatment of COVID‐19 patients, including those who have cancer. Coronavirus disease 2019 (COVID- 19) , the illness caused by a novel severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2), has spread across the world, becoming one of the leading causes of death in some places [1, 2] . The clinical manifestation of COVID-19 infection includes pneumonia, respiratory illness, gastrointestinal and neurological symptoms, and multiple organ damage [3] [4] [5] [6] [7] . In addition to the direct invasion, the immune hyperactivation substantially contributes to the COVID-19 toxicity [7, 8] . As the number of COVID-19 infections surpassed 15 million globally and more than 600,000 infected people have died, according to the World Health Organization (WHO) report [9] , scientists are struggling to understand the viral tropism better and develop the therapeutic approaches for preventing virus infection. Cancer patients belong to a high-risk group for SARS-CoV-2 infection, having a more This article is protected by copyright. All rights reserved severe course of the disease and a high case fatality rate [10] [11] [12] [13] [14] . It can be partially attributed to the older age and the weakened immune system of cancer patients as a consequence of treatment and the immunosuppressive tumor effect [13, 14] . However, no conclusive evidence is yet available explaining the susceptibility of the oncology patients to SARS-CoV-2 infection. The SARS-CoV-2 belongs to β-coronavirus genera and contains a single-stranded, positive-sense RNA genome encoding four structural proteins, including spike (S), nucleocapsid (N), membrane (M) and envelope (E), and several accessory proteins. Coronavirus spike (S) protein mediates the receptor binding of the cell surface and induces the fusion of viral and cellular membranes followed by viral genome entry into human target cells [15] . Analyses of the SARS-CoV-2 genome indicated that the virus uses angiotensin-converting enzyme 2 (ACE2) as the entry receptor [16] that was later confirmed by functional studies of SARS-CoV-2 infection in the hACE2 transgenic mice models [17] . Single-cell RNA sequencing provided evidence that multiple organs with high ACE2 expression, including respiratory tract, lung, esophagus, liver, colon, heart, kidney, ileum, rectum, and stomach, might be vulnerable to SARS-CoV-2 infection [18] . Of note, several types of malignant tumors have high ACE2 expression levels, including colon, kidney, pancreatic, and rectal cancer that can potentially suggest a higher COVID-19 prevalence for patients with these types of malignancies (Figure 1 A, B) . The ACE2 protein was found to be highly expressed in lung adenocarcinoma (LUAD) and lung squamous cell carcinoma (LUSC) [19] that can be associated with a high susceptibility of lung cancer patients to SARS-CoV-2 Infection. On the other hand, SARS-CoV-2 has been reported to efficiently infect cells expressing low ACE2 such as T lymphocytes and other immune cells, suggesting that alternative receptors might mediate the virus entry [20, 21] . In support of this hypothesis, recent studies showed that another cell surface protein CD147 could potentially bind to SARS-CoV-2 spike protein and serve as an additional This article is protected by copyright. All rights reserved infection route [16] (Figure 1 A, C) . CD147 (cluster of differentiation 147) also termed Basigin (BSG), or extracellular matrix metalloproteinase inducer (Emmprin), is a transmembrane glycoprotein with pleiotropic functions that is overexpressed in a broad range of malignant tumors and serves as a promising prognostic biomarker for glioblastoma, colorectal, oral, lung, prostate and many other types of cancer [22] . CD147 has a substantially higher transcription level in both normal and tumor tissues than ACE2 (Figure 1 B) . Furthermore, CD147 plays a role in the inflammatory response as a receptor for Cyclophilin A (CyPA), a potent chemotactic factor for inflammatory leukocytes and activator of the intracellular antiviral response [22] . The CD147-interacting partners, such as integrins, which are also abundant in many types of cancer, are additional candidate receptors for SARS-CoV-2 entry. Still, experimental proof for this hypothesis is required [23] (Figure 1 A, B) . anti-CD147 antibody inhibited SARC-CoV2 replication [16] . According to the preprint report on clinical trial study NCT04275245, Meplazumab improved the outcome of patients with COVID-19-associated pneumonia with a favorable safety profile [24] . Of importance, Meplazumab does not only target the virus replication but also attenuates T-cell chemotaxis induced by CyPA and therefore inhibits COVID-19-associated inflammation [24] . This article is protected by copyright. All rights reserved However, more evidence is warranted to understand the possible correlation between the expression level of CD147 in cells or tissues and SARS-CoV-2 susceptibility. We also need to consider that the most lethal transmission route of SARS-CoV-2 is a lung and bronchial infection. In contrast, the viral concentration in blood is low [25] , and the amount of viral particles that reach each organ through the blood is different. Moreover, in addition to the direct invasion, SARS-CoV-2 might damage multiple organs through collateral effects from cytokine overproduction and clotting. How Large Was the Mortality Increase Directly and Indirectly Caused by the COVID-19 Epidemic? An Analysis on All-Causes Mortality Data in Italy Neurological associations of COVID-19 Manifestations and prognosis of gastrointestinal and liver involvement in patients with COVID-19: a systematic review and meta-analysis Meta-analysis of chest CT features of patients with COVID-19 pneumonia Significance of clinical phenomes of patients with COVID-19 infection: A learning from 3795 patients in 80 reports Clinical features of patients infected with 2019 novel coronavirus in Wuhan, China COVID-19: consider cytokine storm syndromes and immunosuppression COVID-2019) situation reports, The World Health Organization (WHO). Situation report -185 COVID-19 and Cancer: Lessons From a Pooled Meta-Analysis Cancer patients in SARS-CoV-2 infection: a nationwide analysis in China Clinical characteristics of 140 patients infected with SARS-CoV-2 in Wuhan Accepted Article This article is protected by copyright Coronavirus membrane fusion mechanism offers a potential target for antiviral development Genomic characterisation and epidemiology of 2019 novel coronavirus: implications for virus origins and receptor binding Single cell RNA sequencing of 13 human tissues identify cell types and receptors of human coronaviruses Analysis of the susceptibility of lung cancer patients to SARS-CoV-2 infection SARS-CoV-2 infects T lymphocytes through its spike protein-mediated membrane fusion Distribution of ACE2, CD147, CD26 and other SARS-CoV-2 associated molecules in tissues and immune cells in health and in asthma CD147 Is a Promising Accepted Article This article is protected by copyright. All rights reserved Target of Tumor Progression and a Prognostic Biomarker A potential role for integrins in host cell entry by SARS-CoV-2 Meplazumab treats COVID-19 pneumonia: an open-labelled Association of COVID-19 Disease Severity with Transmission Routes and Suggested Changes to Community Guidelines The Phyre2 web portal for protein modeling, prediction and analysis Accelerating and focusing protein-protein docking correlations using multi-dimensional rotational FFT generating functions HexServer: an FFT-based protein docking server powered by graphics processors References: Authors' contributions: XP and AD conceived of the presented idea. XP and AD analyzed the literature, wrote the paper, and approved the final version of the manuscript.